Stephens & Co. Maintains Overweight on Cytek Biosciences, Raises Price Target to $7
Cytek Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
Cytek Biosciences (CTKB) Q3 2026 Earnings Call Transcript
Cytek Biosciences, Inc. Q3 2026 Earnings Call Summary
Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
Cytek Biosciences Inc (CTKB) Q3 2026 Earnings Call Highlights: U.S. ...
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences Q3 Earnings Call Highlights
Cytek Biosciences Reports Third Quarter 2026 Financial Results
Cytek Biosciences Q3 2026 Earnings Call Transcript
Cytek Biosciences Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $53.229M Beat $52.800M Estimate
Cytek Biosciences Narrows FY2026 Sales Guidance from $207.000M-$212.000M to $208.000M-$211.000M vs $209.415M Est
Cytek Biosciences to Participate in Upcoming Investor Conferences
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.